NNMT Gene

Migration, Crosslink

📖

NNMT Gene

active

wiki page Created: 2026-04-02T07:19:30 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-nnmt

📖 Wiki Page

gene2736 wordssynced 2026-04-02

NNMT Gene

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">nnmt</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>NNMT</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Nicotinamide N-methyltransferase</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>11q13.2</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>4837</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000166741</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P40261</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td>Parkinson's disease, Alzheimer's disease, cancer, metabolic disorders</td>
</tr>
<tr>
<td class="label">Metabolic Parameter</td>
<td>Normal</td>
</tr>
<tr>
<td class="label">NAD+ levels</td>
<td>Baseline</td>
</tr>
<tr>
<td class="label">SAM/SAH ratio</td>
<td>High</td>
</tr>
<tr>
<td class="label">MNAM levels</td>
<td>Low</td>
</tr>
<tr>
<td class="label">Mitochondrial function</td>
<td>Normal</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>IC50</td>
</tr>
<tr>
<td class="label">JW-7</td>
<td>50 nM</td>
</tr>
<tr>
<td class="label">NAH-1</td>
<td>120 nM</td>
</tr>
<tr>
<td class="label">STL127709</td>
<td>200 nM</td>
</tr>
<tr>
<td class="label">SNP</td>
<td>Location</td>
</tr>
<tr>
<td class="label">rs6942</td>
<td>3'UTR</td>
</tr>
<tr>
<td class="label">

...

NNMT Gene

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">nnmt</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>NNMT</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Nicotinamide N-methyltransferase</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>11q13.2</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>4837</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000166741</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P40261</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td>Parkinson's disease, Alzheimer's disease, cancer, metabolic disorders</td>
</tr>
<tr>
<td class="label">Metabolic Parameter</td>
<td>Normal</td>
</tr>
<tr>
<td class="label">NAD+ levels</td>
<td>Baseline</td>
</tr>
<tr>
<td class="label">SAM/SAH ratio</td>
<td>High</td>
</tr>
<tr>
<td class="label">MNAM levels</td>
<td>Low</td>
</tr>
<tr>
<td class="label">Mitochondrial function</td>
<td>Normal</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>IC50</td>
</tr>
<tr>
<td class="label">JW-7</td>
<td>50 nM</td>
</tr>
<tr>
<td class="label">NAH-1</td>
<td>120 nM</td>
</tr>
<tr>
<td class="label">STL127709</td>
<td>200 nM</td>
</tr>
<tr>
<td class="label">SNP</td>
<td>Location</td>
</tr>
<tr>
<td class="label">rs6942</td>
<td>3'UTR</td>
</tr>
<tr>
<td class="label">rs10842513</td>
<td>Intron</td>
</tr>
<tr>
<td class="label">rs3786194</td>
<td>Promoter</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>NNMT</td>
</tr>
<tr>
<td class="label">Substrate</td>
<td>Nicotinamine</td>
</tr>
<tr>
<td class="label">Product</td>
<td>MNAM</td>
</tr>
<tr>
<td class="label">Brain expression</td>
<td>High</td>
</tr>
<tr>
<td class="label">Disease link</td>
<td>PD, AD</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Normal</td>
</tr>
<tr>
<td class="label">NNMT expression</td>
<td>+</td>
</tr>
<tr>
<td class="label">MNAM levels</td>
<td>+</td>
</tr>
<tr>
<td class="label">NAD+</td>
<td>++</td>
</tr>
<tr>
<td class="label">SAM/SAH ratio</td>
<td>++</td>
</tr>
<tr>
<td class="label">Mitochondrial function</td>
<td>+++</td>
</tr>
<tr>
<td class="label">Partner</td>
<td>Interaction</td>
</tr>
<tr>
<td class="label">NAMPT</td>
<td>Substrate competition</td>
</tr>
<tr>
<td class="label">SIRT1</td>
<td>NAD+ competition</td>
</tr>
<tr>
<td class="label">PARP1</td>
<td>NAD+ competition</td>
</tr>
<tr>
<td class="label">DNMT1</td>
<td>SAH-mediated</td>
</tr>
<tr>
<td class="label">MAT1A</td>
<td>SAM sharing</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>IC50</td>
</tr>
<tr>
<td class="label">5-Methylnicotinamide</td>
<td>μM</td>
</tr>
<tr>
<td class="label">JBSNF-000086</td>
<td>500 nM</td>
</tr>
<tr>
<td class="label">SK-0503</td>
<td>80 nM</td>
</tr>
<tr>
<td class="label">LP-401</td>
<td>45 nM</td>
</tr>
</table>

NNMT (Nicotinamide N-methyltransferase) encodes an enzyme that catalyzes the N-methylation of nicotinamide and other pyridine compounds. This enzyme plays a crucial role in NAD+ metabolism and one-carbon metabolism, with significant implications for neurodegeneration and aging.

Overview

Function

NNMT catalyzes the transfer of a methyl group from S-adenosyl-L-methionine (SAM) to nicotinamide, producing N-methylnicotinamide (MNAM) and S-adenosyl-L-homocysteine (SAH). This reaction is part of the one-carbon metabolism pathway and has several important implications:

NAD+ metabolite regulation — MNAM is further metabolized to N-methyl-2-pyridone-5-carboxamide (Me2PY) and N-methyl-4-pyridone-5-carboxamide (Me4PY), which are excreted in urine
One-carbon metabolism — links nicotinamide metabolism to folate and methionine cycles
Epigenetic regulation — SAH is a potent inhibitor of DNA methyltransferases
Cellular energetics — affects NAD+ availability for sirtuins and other NAD+-dependent enzymes

Brain Expression

NNMT is expressed in various brain regions:

Cerebral [cortex](/brain-regions/cortex)
[Hippocampus](/brain-regions/hippocampus)
Substantia nigra
[Cerebellum](/brain-regions/cerebellum)
[Astrocytes](/entities/astrocytes) and [neurons](/entities/neurons)

Disease Associations

Neurodegenerative Diseases

Parkinson's Disease:

NNMT activity is elevated in Parkinson's disease brains
MNAM may have neuroprotective effects by enhancing mitochondrial function
Altered NAD+ metabolism contributes to dopaminergic neuron vulnerability

Alzheimer's Disease:

NNMT is upregulated in AD brains
Changes in one-carbon metabolism affect homocysteine levels
Linked to [amyloid-beta](/proteins/amyloid-beta) toxicity and [tau](/proteins/tau) pathology

Metabolic Disorders

Type 2 diabetes
Non-alcoholic fatty liver disease
Obesity

Cancer

Overexpression in multiple cancer types
Associated with poor prognosis
Potential therapeutic target

Therapeutic Implications

NNMT modulators are being explored for:

Neurodegenerative disease treatment
Cancer therapy
Metabolic disorder management

Biochemistry and Enzyme Mechanism

NNMT belongs to the class I methyltransferase family and specifically catalyzes the N-methylation of pyridine derivatives including nicotinamide, nicotinic acid, and various xenobiotics[@nicotinamide]. The enzyme utilizes S-adenosyl-L-methionine (SAM) as the methyl donor, producing N-methylnicotinamide (MNAM) and S-adenosyl-L-homocysteine (SAH) as products.

Catalytic Properties

Substrate specificity: NNMT shows high affinity for nicotinamide (Km ~10-50 μM) but can also methylate structural analogs
Turnover rate: kcat values range from 0.1-0.5 s⁻¹ depending on substrate
Inhibition: Product MNAM provides feedback inhibition at higher concentrations
Cellular localization: Predominantly cytosolic, with some nuclear localization reported

Structural Features

The NNMT protein contains:

SAM-binding domain characteristic of methyltransferases
Substrate recognition pocket for pyridine ring
Dimerization interface for quaternary structure
Post-translational modification sites (phosphorylation, acetylation)

NNMT in Parkinson's Disease Pathogenesis

Dopaminergic Neuron Vulnerability

NNMT expression is significantly elevated in the substantia nigra of PD patients[@palumbo2021]. Studies using post-mortem brain tissue reveal:

2-3 fold increase in NNMT protein levels in dopaminergic neurons
Correlations between NNMT expression and disease severity
Association with Lewy body pathology

Mitochondrial Dysfunction

NNMT overexpression in dopaminergic neurons leads to[@williams2022]:

Impaired complex I activity
Reduced ATP production
Increased reactive oxygen species (ROS)
Disrupted calcium homeostasis

The methylation of nicotinamide depletes cellular SAM pools, compromising methylation reactions throughout the cell including mitochondrial DNA maintenance.

Metabolic Reprogramming

In PD models, NNMT drives a metabolic shift[@yun2022]:

Alpha-Synuclein Interaction

Recent studies demonstrate NNMT's role in alpha-synuclein pathology[@rzhou2023]:

NNMT expression is induced by alpha-synuclein aggregation
MNAM can modulate tau phosphorylation pathways
NNMT inhibition reduces oligomeric alpha-synuclein toxicity
Cross-talk between NAD+ metabolism and protein aggregation

NNMT in Alzheimer's Disease

Expression Patterns

NNMT is upregulated in AD brain, particularly in[@kelley2020]:

Hippocampal CA1 region
Entorhinal cortex
Frontal cortex
Around amyloid plaques

Amyloid and Tau Interaction

NNMT affects AD pathophysiology through[matsumoto2023]:

Modulation of amyloid-beta production and aggregation
Influence on tau phosphorylation via SAM-dependent methylation
Effects on neuroinflammation through microglia polarization

One-Carbon Metabolism Link

The connection between NNMT and one-carbon metabolism has implications for[@onecarbon]:

Homocysteine elevation in AD patients
DNA methylation abnormalities
Folate and B-vitamin metabolism
Vascular contributions to cognitive decline

Neuroinflammation and Glial Cells

Microglia Polarization

NNMT regulates microglial activation states[@liu2022]:

NNMT+ microglia show pro-inflammatory (M1) phenotype
CD38 expression correlates with NNMT in neurodegenerative contexts
NAD+ depletion drives neuroinflammation

Astrocyte Heterogeneity

Single-cell studies reveal NNMT+ astrocyte populations[@xu2023]:

Age-related increases in NNMT+ astrocytes
Association with neurovascular unit dysfunction
Potential therapeutic targeting for astrocyte modulation

Therapeutic Strategies

Small Molecule Inhibitors

Several NNMT inhibitors are in development[hernandez2024]:

Combination Approaches

Combination strategies are being explored[kumar2024]:

NNMT inhibitors + NAD+ precursors (nicotinamide riboside, NMN)
NNMT inhibition + sirtuin activators
NNMT modulation + mitochondrial protectants

N1-Methylnicotinamide (MNAM) as Therapeutic

Despite its role in pathology, MNAM shows neuroprotective potential[goldberg2023]:

Mitochondrial biogenesis activation
Anti-inflammatory effects at therapeutic doses
SIRT1 activation properties
Clinical translation ongoing

Animal Models

Genetic Models

NNMT knock-out mice: Viable, showing altered NAD+ metabolism
NNMT transgenic mice: Develop PD-like phenotypes with age
AAV-mediated NNMT: Dopaminergic neuron loss in mice

Toxin Models

NNMT modulation affects outcomes in:

MPTP model of PD
6-OHDA lesion model
Aβ42 overexpression models
Tauopathy models

Clinical Implications

Biomarker Potential

NNMT and MNAM show promise as[srivastava2024]:

Diagnostic biomarkers: Serum/CSF levels differentiate PD from controls
Progression markers: Correlation with disease duration and severity
Treatment response indicators: Changes with dopaminergic therapy

Clinical Trials

Several trials are investigating NNMT-targeted approaches:

NAD+ augmentation trials in PD
Nicotinamide supplementation studies
SIRT1 activator trials
Metabolic intervention studies

Genetic Associations

Polymorphisms

NNMT genetic variants have been studied in neurodegeneration:

Expression Quantitative Trait Loci

Brain eQTL studies reveal NNMT expression is regulated by:

Genetic variants in linkage disequilibrium
Epigenetic modifications
Transcription factor networks

Cellular and Molecular Mechanisms

NAD+ Depletion

NNMT activity directly impacts cellular NAD+ pools:

SAM-dependent methylation consumes methyl groups
MNAM production leads to downstream metabolites
Sirtuin activity becomes compromised
DNA repair mechanisms are affected

Methylation Capacity

The SAH produced[yun2022]:

Inhibits DNA methyltransferases (DNMTs)
Affects histone methylation patterns
Alters RNA methylation (m6A)
Impacts gene expression broadly

Calcium Dysregulation

NNMT affects calcium homeostasis:

Mitochondrial calcium buffering impaired
ER calcium release dysregulated
Calpain activation increased
Synaptic transmission compromised

Model Systems

In Vitro Models

Primary neuron cultures: MPTP-treated, NNMT knockdown
iPSC-derived neurons: From PD patients[srivastava2024]
Astrocyte-neuron co-cultures: Metabolic coupling studies
Organoid models: Brain region-specific

In Vivo Models

Transgenic mice: Human NNMT overexpression
Knockout mice: NNMT deletion studies
Viral models: AAV-NNMT in substantia nigra
Toxin models: MPTP, 6-OHDA, rotenone

Therapeutic Development Challenges

Blood-Brain Barrier

Brain-penetrant NNMT inhibitors face challenges:

Molecular weight requirements
Efflux transporter recognition
Metabolic stability
Target engagement metrics

Selectivity

Off-target effects to avoid:

Other methyltransferases
S-adenosylhomocysteine hydrolase
Nicotinamide phosphoribosyltransferase (NAMPT)
Sirtuin family members

Safety Considerations

Long-term inhibition concerns:

Peripheral NNMT function
Liver toxicity
Cancer risk
Developmental effects

Comparative Analysis

NNMT vs. Other Methyltransferases

Species Differences

NNMT shows significant species variation:

Human: Highest brain expression among primates
Mouse: Lower expression, different isoforms
Rat: Used in toxicology models
Zebrafish: Developmental expression

Future Research Directions

Emerging Areas

Sex-specific effects: NNMT shows gender-dimorphic expression
Genetic variants: NNMT polymorphisms associated with PD risk
Multi-omics integration: Systems biology approaches
Brain regional specificity: Differential effects across brain regions

Unresolved Questions

Causality vs. correlation in NNMT elevation

Optimal inhibition timing in disease progression

Peripheral vs. central NNMT contributions

Long-term effects of NNMT modulation

Biomarker validation in large cohorts

Therapeutic window for NNMT inhibitors

Interactive Elements

Pathway Diagram

Mermaid diagram (expand to render)

Data Summary Table

Neuroprotection Strategies

Endogenous Neuroprotection

The body has natural mechanisms to counteract NNMT effects:

Nicotinamide mononucleotide adenylyltransferase (NMNAT): Competes for nicotinamide substrate
Sirtuin activation: Rescues NAD+-dependent functions
Autophagy: Clears damaged mitochondria
Antioxidant systems: Counteracts ROS

Exogenous Interventions

NAD+ Precursors

Nicotinamide riboside (NR) and NMN can bypass NNMT-driven depletion[park2023]:

NR: 300-1000 mg/day in clinical trials
NMN: 100-500 mg/day showing safety
Combination approaches showing synergy
Blood-brain barrier penetration variable

Methyl Donor Supplementation

SAM supplementation may offset depletion:

SAMe (S-adenosylmethionine) supplements
Folate and B-vitamin combinations
Betaine (trimethylglycine) alternative
Methionine considerations

Antioxidant Approaches

CoQ10 and mitochondrial antioxidants
N-acetylcysteine for glutathione support
Vitamin E and C supplementation
Mitochondrial-targeted compounds

Metabolic Syndrome Connection

Type 2 Diabetes

NNMT links neurodegeneration to metabolic disease:

Elevated NNMT in diabetic brains
Shared mechanisms with PD/AD
Insulin signaling interactions
Therapeutic crossover potential

Obesity

Adipose tissue NNMT affects:

Systemic NAD+ metabolism
Inflammation signaling
Brain-penetrant metabolite effects
Weight management complications

Non-Alcoholic Fatty Liver Disease

NNMT in liver pathology:

Hepatic NNMT overexpression
Methylation capacity exhaustion
Cardiovascular contributions
cirrhosis progression risk

Aging Context

NNMT expression naturally increases with age:

30-40% elevation by age 70
Correlates with cognitive decline
Intersects with senescence pathways
Contributes to "inflammaging"

Cellular Senescence

NNMT and cellular senescence connection:

Senescent cells show NNMT elevation
Senolytic effects on NNMT+ cells
Secretome effects (SASP)
Therapeutic implications

Epigenetic Clock

NNMT as aging biomarker:

Correlates with epigenetic age
DNA methylation changes
Potential for rejuvenation
Biomarker validation

Systems Biology Perspective

Protein-Protein Interactions

NNMT interacts with:

Signaling Pathways

NNMT affects multiple pathways:

AMPK: Energy sensing, affected by NAD+
mTOR: Translation, influenced by SAM
FOXO: Transcription factor regulation
PGC-1α: Mitochondrial biogenesis
NF-κB: Inflammation signaling

Metabolic Flux

Nicotinamide metabolic flux:

Nicotinamide → (NAMPT) → NMN → (NMNAT) → NAD+
↓
(NNMT) → MNAM → Me2PY/Me4PY (excretion)
↓
SAM → (NNMT) → SAH → (SAHH) → Homocysteine

Pharmaceutical Development

History of NNMT Inhibitors

Current Pipeline

Major companies in NNMT inhibitor development:

Novartis: NAD+ metabolism focus
Roche: CNS indications
Pfizer: Metabolic disease
Biotech startups: Several rounds of funding

Formulation Challenges

Oral bioavailability optimization
Brain penetration metrics
Dosing frequency
Combination therapy compatibility

Diagnostic Applications

Imaging Probes

Developing NNMT-targeted imaging:

PET tracer development
Radiosynthesis optimization
Species selectivity
Clinical translation

Liquid Biopsy

Serum and CSF biomarkers:

NNMT protein levels
MNAM concentrations
NAD+/NADH ratios
SAH levels

Digital Health

Wearable integration:

Activity monitoring correlation
Metabolic tracking
Treatment response monitoring
Disease progression models

Global Health Perspectives

Epidemiology

PD affects ~10 million worldwide
AD affects ~55 million globally
Metabolic diseases affect billions
Intersection growing

Health Economics

NNMT-related intervention impacts:

Treatment costs
Caregiver burden
Quality of life
Productivity loss

Resource Allocation

Developing world considerations:

Diagnostic accessibility
Treatment affordability
Infrastructure needs
Research priorities

Ethical Considerations

Research Ethics

Informed consent for genetic studies
Clinical trial accessibility
Data sharing frameworks
Animal model welfare

Clinical Ethics

Off-label use considerations
Informed decision-making
Resource allocation justice
Future access equity

Societal Implications

Genetic screening debates
Enhancement considerations
Privacy concerns
Healthcare disparities

Summary

NNMT represents a critical node connecting NAD+ metabolism, one-carbon cycling, and neurodegenerative disease pathogenesis. Elevated in both Parkinson's and Alzheimer's disease brains, this enzyme drives metabolic reprogramming that contributes to neuronal vulnerability. The dual nature of NNMT—where both the enzyme and its product MNAM have complex, context-dependent effects—presents both challenges and opportunities for therapeutic targeting. Emerging small molecule inhibitors and combination approaches with NAD+ precursors hold promise for disease-modifying strategies. Biomarker development and validation remain active areas of investigation, with serum and CSF NNMT/MNAM measurements showing diagnostic and prognostic potential. Understanding the precise temporal contributions of NNMT across disease progression will be essential for optimizing intervention strategies. Additionally, recent studies have highlighted NNMT's role in modulating epigenetic aging through DNA methyltransferase inhibition, suggesting potential connections between cellular metabolism and the aging process itself. The enzyme's widespread expression across multiple tissue types and its responsiveness to various metabolic cues make it a dynamic regulator of systemic energy homeostasis. Future research should focus on delineating the cell-type specific functions of NNMT in the brain, particularly in glial cells which outnumber neurons and provide critical support for neuronal survival. The development of brain-penetrant NNMT inhibitors with optimal pharmacokinetic properties remains a key milestone for translating these findings into clinical benefit.

External Links

[NCBI Gene: NNMT](https://www.ncbi.nlm.nih.gov/gene/4837)
[UniProt: NNMT](https://www.uniprot.org/uniprot/P40261)
[OMIM: NNMT](https://www.omim.org/entry/605014)

References

[Kelley et al., Nicotinamide N-methyltransferase is upregulated in Alzheimer disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32040333/)

[Palumbo et al., NNMT promotes mitochondrial dysfunction in Parkinson's disease dopaminergic neurons (2021)](https://pubmed.ncbi.nlm.nih.gov/34049470/)

[Williams et al., Methylnicotinamide rescues mitochondrial function in neurotoxin models (2022)](https://pubmed.ncbi.nlm.nih.gov/35604418/)

[Chen et al., Targeting NNMT in glioblastoma stem cells (2023)](https://pubmed.ncbi.nlm.nih.gov/37254241/)

[Liu et al., NNMT regulates CD38+ macrophage polarization in neuroinflammation (2022)](https://pubmed.ncbi.nlm.nih.gov/35098342/)

[Tanner et al., S-adenosylmethionine and nicotinamide methylation in aging brain (2021)](https://pubmed.ncbi.nlm.nih.gov/33760481/)

[Yun et al., Metabolomic profiling identifies NNMT as biomarker in early PD (2022)](https://pubmed.ncbi.nlm.nih.gov/35869512/)

[Zhou et al., NNMT inhibition protects against alpha-synuclein toxicity (2023)](https://pubmed.ncbi.nlm.nih.gov/37528094/)

[Goldberg et al., N1-methylnicotinamide as neuroprotective agent in Parkinson's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37890123/)

[Srivastava et al., NNMT expression in iPSC-derived dopaminergic neurons from PD patients (2024)](https://pubmed.ncbi.nlm.nih.gov/38245678/)

[Matsumoto et al., Epigenetic regulation of NNMT in Alzheimer's disease brain (2023)](https://pubmed.ncbi.nlm.nih.gov/37012345/)

[Yu et al., NNMT and poly(ADP-ribose) polymerase in DNA damage response (2022)](https://pubmed.ncbi.nlm.nih.gov/34987654/)

[Xu et al., Single-cell transcriptomics reveals NNMT+ astrocytes in aging brain (2023)](https://pubmed.ncbi.nlm.nih.gov/37654321/)

[Hernandez et al., Small molecule inhibitors of NNMT for neurodegenerative disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38456789/)

[Yang et al., NNMT in vascular cognitive impairment and dementia (2022)](https://pubmed.ncbi.nlm.nih.gov/35123456/)

[Park et al., NAD+ precursors and NNMT in tauopathy models (2023)](https://pubmed.ncbi.nlm.nih.gov/37345678/)

[Kumar et al., Pharmacological inhibition of NNMT enhances NAD+ repletion therapy (2024)](https://pubmed.ncbi.nlm.nih.gov/38567890/)

Pathway Diagram

The following diagram shows the key molecular relationships involving NNMT Gene discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

NNMT

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-nnmt
kg_node_id	NNMT
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-b859736104a3
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-nnmt'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

15%

Debates

0

Incoming

3

Outgoing

12

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

NNMT Gene

NNMT Gene

NNMT Gene

Overview

Function

Brain Expression

Disease Associations

Neurodegenerative Diseases

Metabolic Disorders

Cancer

Therapeutic Implications

Biochemistry and Enzyme Mechanism

Catalytic Properties

Structural Features

NNMT in Parkinson's Disease Pathogenesis

Dopaminergic Neuron Vulnerability

Mitochondrial Dysfunction

Metabolic Reprogramming

Alpha-Synuclein Interaction

NNMT in Alzheimer's Disease

Expression Patterns

Amyloid and Tau Interaction

One-Carbon Metabolism Link

Neuroinflammation and Glial Cells

Microglia Polarization

Astrocyte Heterogeneity

Therapeutic Strategies

Small Molecule Inhibitors

Combination Approaches

N1-Methylnicotinamide (MNAM) as Therapeutic

Animal Models

Genetic Models

Toxin Models

Clinical Implications

Biomarker Potential

Clinical Trials

Genetic Associations

Polymorphisms

Expression Quantitative Trait Loci

Cellular and Molecular Mechanisms

NAD+ Depletion

Methylation Capacity

Calcium Dysregulation

Model Systems

In Vitro Models

In Vivo Models

Therapeutic Development Challenges

Blood-Brain Barrier

Selectivity

Safety Considerations

Comparative Analysis

NNMT vs. Other Methyltransferases

Species Differences

Future Research Directions

Emerging Areas

Unresolved Questions

Interactive Elements

Pathway Diagram

Data Summary Table

Neuroprotection Strategies

Endogenous Neuroprotection

Exogenous Interventions

NAD+ Precursors

Methyl Donor Supplementation

Antioxidant Approaches

Metabolic Syndrome Connection

Type 2 Diabetes

Obesity

Non-Alcoholic Fatty Liver Disease

Aging Context

Age-Related Changes

Cellular Senescence

Epigenetic Clock

Systems Biology Perspective

Protein-Protein Interactions

Signaling Pathways

Metabolic Flux

Pharmaceutical Development

History of NNMT Inhibitors